Matches 1 - 50 out of 59 1 2 >


Match Document Document Title
US20110293723 SYNTHETIC NANOCARRIER COMBINATION VACCINES  
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are...
US20120276145 EXTRACELLULAR MATRIX PROTEINS FROM HAEMOPHILUS INFLUENZAE BIOFILMS: TARGETS FOR THERAPEUTIC OR DIAGNOSTIC USE  
A method of identifying a biofilm that includes non-typeable Haemophilus influenza (NTHi) including a step of screening a sample for the presence of one or more biofilm-specific proteins that are...
US20110206765 Non-Typeable Haemophilus Influenzae Vaccines and Their Uses  
Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a...
US20110081357 Chimeric Vaccine for Haemophilus Influenzae-Induced Disease  
The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention...
US20150037370 DIATOM-BASED VACCINES  
This invention provides diatom-based vaccines.
US20140186399 PROTEIN MATRIX VACCINES AND METHODS OF MAKING AND ADMINISTERING SUCH VACCINES  
The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
US20120003277 NANOEMULSION VACCINES  
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more...
US20150098968 HAEMOPHILUS PARASUIS VACCINE SEROVAR TYPE FOUR  
The present invention is a Haemophilus parasuis vaccine against serovar type 4 capable of triggering a protective immune response when administered to pigs as a killed vaccine. The present...
US20120225091 MODIFIED LIVE (JMSO STRAIN) HAEMOPHILUS PARASUIS VACCINE  
The present invention is a live vaccine from a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered...
US20120020979 METHODS FOR TREATING IgE-MEDIATED DISORDER  
This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods...
US20100150967 TREATMENT OR PROPHYLAXIS OF ASTHMA  
There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae...
US20140178435 VACCINE COMPRISING INACTIVATED CELLS OF HAEMOPHILUS PARASUIS BACTERIA OF SEROTYPE 5  
The present invention pertains to the use of Haemophilus parasuis bacteria of serotype 5 expressing an iron-restriction protein visible on a Western-blot when reacted with serum of a convalescent...
US20130039941 VACCINE COMPRISING INACTIVATED CELLS OF HAEMOPHILUS PARASUIS BACTERIA OF SEROTYPE 5  
The present invention pertains to the use of Haemophilus parasuis bacteria of serotype 5 expressing an iron-restriction protein visible on a Western-blot when reacted with serum of a convalescent...
US20140154329 Process For Stabilizing An Adjuvant Containing Vaccine Composition  
The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an...
US20140023684 Vaccine Against Pasteurellaceae  
The invention relates to vaccines providing protection against infections caused by members of the Pasteurellaceae family comprising outer membrane vesicles as the only active components, wherein...
US20110223174 Nontypeable Haemophilus Influenzae Virulence Factors  
The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes...
US20120244182 USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION  
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance...
US20110014237 Vaccine for Protection Against Haemophilus Parasuis Serotype 4 in Piglets  
The present invention pertains to the use of Haemophilus parasuis serotype 5 bacteria in the manufacture of a vaccine for administration to a pregnant sow or gilt, to protect a piglet through the...
US20110159030 MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS  
A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune...
US20150202274 PURIFICATION OF BACTERIAL VESICLES  
A two stage filtration process is used to purify immunogenic bacterial vesicles. A first step separates the vesicles from intact bacteria based on their different sizes, with the smaller vesicles...
US20090017074 CULTURE MEDIUM FOR HAEMOPHILUS INFLUENZAE TYPE B  
The invention relates to a culture medium for Haemophilus influenzae type b, characterized in that the source of protein nitrogen is of non-animal origin and comprises at least one plant peptone...
US20120237544 BACTERIAL SPORE HAVING THERAPEUTIC AGENT ADSORBED ON ITS SURFACE  
The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present...
US20130337006 POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES  
The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.
US20120195937 POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES  
The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.
US20100255035 Modified live (JMSO strain) Haemophilus parasuis vaccine  
The present invention is a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs as a live...
US20120171244 MUCOSAL BOOSTING FOLLOWING PARENTERAL PRIMING  
Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described.
US20140294894 TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS  
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to...
US20110142881 TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS  
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to...
US20070269376 Method for Determining Dosage for an Oral Killed Vaccine  
There is disclosed a method for determining an administration regimen for an oral killed vaccine for use in immunising individuals in a population against an infection or disease. The method...
US20100233201 VACCINE COMPOSITION  
The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or...
US20100310569 Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae  
The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also...
US20080044440 Vaccine Formulated For Administration To Mucosa Of The Lungs  
There is disclosed vaccines formulated for administration to the mucosa of the lungs of a mammal, and the use thereof in methods for prophylaxis or treatment of an infection by at least one...
US20140141041 RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC  
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of...
US20090110699 Antigen-Adjuvant Compositions and Methods  
Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions,...
US20100285064 ADJUVANT COMPOSITION FOR VACCINE  
The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.
US20060121059 Vaccine composition  
The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or...
US20140193457 IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES  
The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or...
US20140120135 AQUEOUS COMPOSITION COMPRISING A BIOLOGICAL ANTIGEN AND AN ACRYLIC ACID POLYMER  
The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity...
US20100272758 Viable non-toxic gram-negative bacteria  
The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking...
US20100285070 POLYNUCLEOTIDES OF HAEMOPHILUS PARASUIS AND ITS USE  
The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a...
US20100074922 Pneumococcal polysaccharide conjugate vaccine  
The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various...
US20140287043 COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS  
Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of...
US20090297559 USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS  
The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used...
US20090155330 Vaccine Delivery via Microneedle Arrays  
A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have...
US20110300179 Novel Compositions and Uses Thereof  
The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells...
US20110200616 Immunizing Compositions and Methods of Use  
The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater...
US20050153872 Methods and compositions for the treatment of infection  
The invention described herein provides novel compositions and methods for treating infection caused by, for example, bacteria, fungi, or virus.
US20080095803 Protein matrix vaccines and methods of making and administering such vaccines  
The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
US20140314803 COMPOSITIONS AND METHODS RELATED TO P6  
Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM.
US20130156803 COMPOSITIONS AND METHODS RELATED TO P6  
Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM.

Matches 1 - 50 out of 59 1 2 >